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remodeling in several physiological conditions such as 
pregnancy, lactation and the estrous cycle  [3] .
 The expression of estrogen receptor (ER) forms and 
other proteins interacting with the receptor markedly in-
fluences overall activity of estrogens in a given cell. Ge-
nomic effects of estrogens as well as factors determining 
estrogen action in the hypothalamic-pituitary axis were 
reviewed several years ago  [4] . Since then, information on 
classical ERs and particularly on intracellular signaling 
pathways involved in non-classical mechanisms of estro-
gen action in the anterior pituitary gland has grown. This 
review is an updated summary of mechanisms of estro-
gen action in anterior pituitary cells, mainly in rodent 
experimental models.
 Estrogen Receptor Structure 
 Most biological actions of estrogens take place through 
ERs. The two classical ERs, ER  and ER  , belong to the 
superfamily of nuclear receptors, specifically the family 
of steroid receptors that act as ligand-regulated transcrip-
tion factors  [5] . These ER isoforms are encoded by sepa-
rate genes located on different chromosomes  [6] . ERs are 
composed of an N-terminal region domain, a DNA-bind-
ing domain, a hinge domain, a ligand-binding domain 
and a C-terminal domain. ERs act as dimers and their 
transcriptional activity is mediated by synergy between 
two activation domains, a constitutively active AF-1 at 
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 Abstract 
 Estrogens are crucial determinants in the regulation of ante-
rior pituitary function and maintenance of tissue homeosta-
sis. Estrogen actions in this gland are exerted through both 
classical and non-classical mechanisms of action. This review 
summarizes the expression of classical   - and   -estrogen re-
ceptors and variant isoforms of estrogen receptors in ante-
rior pituitary cell subpopulations. We also analyze estrogen 
receptor signaling pathways involved in estrogenic actions 
in the anterior pituitary gland, especially in lactotropes and 
somatotropes. Complex interactions between multiple sig-
naling pathways are involved in estrogen regulation of hor-
mone secretion, cell proliferation and cell death in this gland. 
Insight into these pituitary responses to estrogens would 
help to understand pituitary function and tumorigenesis. 
 Copyright © 2010 S. Karger AG, Basel 
 Estrogens regulate gene expression and influence cru-
cial physiological events in target tissues. They are also 
essential for reproductive functions in the female, stimu-
lating secretion of gonadotropins and prolactin  [1, 2] . Es-
trogens also play an important role in anterior pituitary 
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the N terminus and a ligand-dependent AF-2 in the li-
gand-binding domain  [7] .
 ER  and ER  are more than 95% homologous in the 
DNA-binding domain and about 59% in the ligand-bind-
ing domain, but differ in the C-terminal domain and the 
N-terminal transactivation domain  [6] . The N-terminal 
domain is the most variable region, suggesting that these 
two isoforms might interact differently with proteins, 
thereby contributing to ER subtype-specific action on 
target genes  [7] .
 Receptor activation by 17  -estradiol (E 2 ) requires a 
conformational change in the ligand-binding domain 
that includes formation of a hydrophobic pocket and 
modification of the surface that facilitates interaction 
with coregulatory proteins that may either enhance or 
suppress ER-dependent transcriptional activity  [5] . Many 
coregulators are enzymes that modify proteins through 
several mechanisms, including acetylation, methylation, 
phosphorylation and chromatin remodeling at sites 
where ERs are attached  [5, 7, 8] . Coactivators such as ste-
roid receptor coactivator-1 (SRC-1), SRC-2 and SRC-3 in-
crease ER-mediated transcription by chromatin remod-
eling through histone acetyltransferase activity and re-
cruitment of other coactivators, including CREB-binding 
protein (CBP) and p300/CBP-associated factor  [8] . His-
tone methylation, catalyzed by histone methyltransfer-
ases and reversed by histone demethylases, also modu-
lates nuclear hormone signaling  [9] . Corepressors sup-
press or silence gene expression by methylation of DNA 
and by binding to methyl-CpG-binding proteins that re-
cruit corepressor complexes and histone deacetylase. 
Some corepressors of nuclear receptors are the nuclear 
receptor corepressor (NcoR), the silencing mediator of 
retinoid and thyroid hormone receptors (SMRT) and the 
repressor of ER activity (REA). Nuclear receptor coregu-
lators are molecules critical for modulating steroid-re-
ceptor-mediated transcription. The capacity of ERs to re-
cruit different coregulators may explain cell-specific re-
sponses to estrogens  [8] .
 Several variant isoforms of ER mRNAs and proteins 
exist for both ER  and ER  subtypes  [7] . The splice vari-
ants could result from deletion of one or more coding 
exons or base insertion within an exon  [4] . Truncated es-
trogen receptor products 1 and 2 (TERP-1 and TERP-2) 
are truncated forms of ER  lacking the N-terminal, 
DNA-binding and hinge regions and part of the hor-
mone-binding domain but contain specific upstream se-
quences  [4] . In physiological conditions in the female rat, 
TERP-1 expression is limited to the pituitary  [4] . TERP-1 
cannot bind to DNA and thereby does not affect gene ex-
pression by itself but can modulate the action of full-
length ERs, depending on cell and promoter context  [4] . 
TERP-1 forms heterodimers with either ER  or ER  . 
With high TERP-1:ER  ratios, TERP-1 can dimerize 
with ER  , inhibiting ER  from binding to its DNA re-
sponse elements  [10] . TERP-1 can also suppress ER  
transcriptional activity by competition for coactivators 
such as SRC-1  [10] . On the other hand, TERP-1 at low 
concentrations can stimulate ER  transcriptional activ-
ity by titration of corepressors such as REA  [11] .
 Although classical ERs are located mostly in the nu-
cleus, estrogen-binding proteins have also been localized 
in extranuclear compartments, such as the plasma mem-
brane, mitochondria and the endoplasmic reticulum  [12, 
13] . Since the first identification of specific binding sites 
for estrogen at the outer surface of endometrial cells over 
30 years ago  [14] , considerable research has been done on 
this area, defining key aspects of the nature and functions 
of extranuclear ERs. Although ER  and ER  present at 
the membrane could be transmembrane proteins, these 
receptors are more generally accepted to be membrane-
associated, anchored by scaffold proteins to the inner 
leaflet of the membrane  [12, 13, 15] . Palmitoylation of a 
residue in the ligand-binding domain promotes associa-
tion of ER with caveolin-1, a necessary transporter of 
ER  to caveolae rafts in the plasma membrane  [12, 13] . 
ERs are considered a central component of a membrane 
complex containing several molecules including G-pro-
teins, heat-shock protein 90, c-Src homology, collagen ho-
mology (Shc) and modulator of non-genomic activity of 
the ER (MNAR), which are critical in rapid estrogenic ac-
tions  [13] . A small fraction of ERs is localized within mi-
tochondria  [16] . Mitochondrial ER was reported to de-
crease reactive oxygen species production by activation of 
MnSOD  [16] . The orphan G-protein-coupled receptor 
(GPR30), a controversial ER reported to be localized at 
the plasma membrane and the endoplasmic reticulum 
 [17, 18] , failed to stimulate estrogen actions and therefore 
may not be an ER  [13] .
 Regulation of the Expression of Estrogen Receptors 
and Receptor Variants in the Pituitary 
 Cell-specific actions of estrogens in the rat pituitary 
can result from modulated expression of ER isoforms. 
The anterior pituitary gland of the adult female rat ex-
presses classical ERs, ER  and ER  , and TERP-1. Both 
ER  and ER  are transcribed from several alternate first 
exons and multiple promoters whereas TERP-1 is tran-
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scribed from a promoter different from those for ER   [4] . 
ER  was reported to be expressed in varying proportions 
in all the secretory populations of the anterior pituitary 
as well as in folliculo-stellate cells  [19, 20] . ER  is local-
ized mainly in lactotropes, followed by somatotropes and 
gonadotropes. The percentage of ER  -expressing cells is 
lower than that of ER  -bearing cells and only a small pro-
portion of pituitary cells coexpresses both receptors  [19, 
20] . In humans, ER  was not detected in GH-producing 
cells  [4] . The rat pituitary also expresses TERP-1 and 
TERP-2 mRNA, which have not been detected in other 
tissues. TERP-1 protein is localized primarily in lacto-
tropes and gonadotropes  [19] .
 Strong evidence indicates that ER  expression varies 
during the estrous cycle with its highest expression at 
proestrus whereas ER  mRNA levels were found to re-
main relatively constant in rats  [20, 21] or to be higher at 
proestrus than at diestrus in bitches  [22] . Conversely, 
ER  mRNA was reported not to change significantly 
across the estrous cycle whereas ER  levels fall in the 
morning of proestrus  [4] . ER  expression is higher in fe-
male rats than in males  [4] . TERP-1 mRNA begins to rise 
at diestrus and peaks at proestrus. Estrogen treatment of 
ovariectomized rats does not regulate ER  transcription 
and slightly decreases ER  mRNA levels but dramatical-
ly induces TERP-1 mRNA  [23] . Through ER  , endoge-
nous estrogens differentially regulate expression of 
mRNAs by encoding several ER isoforms  [24] . Both ER  
and the pituitary-specific transcription factor Pit-1 act at 
the proximal promoter region of TERP-1 gene and are es-
sential for full promoter activity  [25] .
 Classical ERs and TERP-1 proteins are also modulated 
by gonadal steroids  [4] . TERP-1 protein levels increase 
dramatically with estrogens and thus the TERP-1:ER  
protein ratio can be very high at proestrus  [4] . Although 
ER  expression is relatively constant during pregnancy 
and lactation, TERP-1 expression is highly increased in 
mid- to late pregnancy  [26] . It was also demonstrated that 
TERP-1 mRNA and protein are stimulated by E 2 in pitu-
itary cell lines such as GH3 somatolactotrope cells, MMQ 
lactotrope cells and L  T2 gonadotrope cells  [25, 27] .
 Estrogen-binding proteins associated with the plasma 
membrane have been detected in the anterior pituitary 
gland  [28] . Membrane-associated ER  (mER  ) was 
found in GH3  [29] and in normal lactotropes  [30, 31] , 
whereas mER  was not found in these cells  [30] . mER  
was also detected in the plasma membrane of somato-
tropes  [31] . Expression of mER  in lactotropes is higher 
at proestrous than at diestrus and is estrogen-dependent 
[Zárate et al., unpubl. results].
 Mechanisms of Estrogen Action 
 ERs signal through multiple pathways, which can be 
classified as either classical, involving specific estrogen 
response element- (ERE), or non-classical, involving 
ERE-independent mechanisms  [32] . The classical mecha-
nism of estrogen action involves binding of estrogens to 
intracellular ERs, induction of conformational changes 
in the receptor leading to dimerization, interaction with 
coregulator molecules and binding of this complex to 
ERE- or ERE-like sequences in the regulatory regions of 
target genes to either activate or repress gene expression. 
Non-classical, ERE-independent pathways of estrogen 
action include: (1) regulation of gene expression via pro-
tein-protein interactions between ligand-bound ERs and 
other transcription factors such as SP-1, c-Fos/c-Jun B 
(AP-1) and NF-  B; (2) ligand-independent ER signaling, 
in which second-messenger pathways modify the activity 
of intracellular kinases and phosphatases that alter the 
state of phosphorylation and transcriptional activity of 
ERs, and (3) rapid, membrane-initiated estrogen actions 
in which activation of membrane-associated ERs initiate 
second-messenger pathways that modulate the phos-
phorylation status and hence the activity of cytoplasmic 
proteins such as Bax or eNOS as well as other transcrip-
tion factors such as cAMP response element-binding pro-
tein (CREB)  [33] . In this way, through membrane initi-
ated pathways, estrogens can regulate transcription indi-
rectly  [32] . Studies in recent years suggest a high degree 
of interaction between membrane-initiated signaling 
pathways and both classical and non-classical intracellu-
lar signaling pathways to ultimately accomplish a physi-
ological end-point  [34] ( fig. 1 ).
 Multiple molecular mechanisms are involved in estro-
gen-induced hormone synthesis and release, cell prolif-
eration and death in the pituitary. Estrogen actions on 
gonadotropes are well documented and reviewed else-
where  [1] . Considering that lactotropes are the anterior 
pituitary cell population with the highest turnover dur-
ing the estrous cycle followed by somatotropes, the mech-
anisms of estrogen action on these pituitary populations 
will be discussed.
 Prolactin Secretion 
 Estradiol is a major regulator of prolactin (PRL) secre-
tion  [35] . Within the rat anterior pituitary, estradiol con-
trols PRL gene expression by direct binding of activated 
ERs to specific DNA sequences located in the promoter 
of the rat PRL (rPRL) gene  [35] . Also, the rPRL gene con-




required for both basal as well as estrogen-induced PRL 
gene expression  [36, 37] . The development of cell lines 
derived from pituitary tumors has largely contributed to 
the study of PRL secretion at the cellular and molecular 
level. However, the functional heterogeneity of cell lines 
raises the concern of considering them as representing 
normal lactotropes. For instance, different GH3 cell sub-
clones can release GH only, PRL only, both hormones or 
neither  [35] . Thus, data collected from cell lines must be 
considered carefully when drawing conclusions that ap-
ply to normal lactotropes. An estrogen-dependent physi-
cal interaction between ER and Pit-1 protein has been 
shown in GH3 and PR1 lactotrope cell lines  [38] . The 
rPRL promoter also contains binding sites for other tran-
scription factors, some of whose functions are regulated 
by protein kinases activated by MAPK and/or PKA path-
ways, suggesting a possible role of non-classical estrogen 
regulation of gene expression through ERE-independent 
pathways. It was reported that E 2 -induced rapid and tran-
sient activation of ERK1/2 by a mechanism likely involv-
ing c-Raf-1 is required for PRL gene transcription in both 
GH3 and PR1 cells  [39] . Direct phosphorylation of a 
MAPK-responsive transcription factor and changes in 
the phosphorylation status of ER by MAPKs are mecha-
nisms suggested to be involved in E 2 -induced PRL gene 
expression in these cells  [39] . Recently, EGF through 
ErbB1 activation was reported to cross-talk with ER  to 
stimulate PRL gene expression in GH3 cells. This EGF 
action is mediated by ERK1/2-induced S118 phosphoryla-
tion of ER  , indicating that non-classical, ligand-inde-
pendent ER signaling is involved in EGF-induced PRL 
expression in these cells  [40] . Another recent report also 
showed interaction between bone morphogenetic pro-
tein-4 (BMP-4) and estrogen intracellular signaling path-
 Fig. 1. Mechanisms of estrogen action via ERs in the pituitary. ER 
signaling includes: classical ERE-dependent, in which liganded 
ER dimerizes and binds to ERE- or ERE-like sequences in the 
promoter of target genes; non-classical ligand-independent, in 
which the ER is activated by phosphorylation in the absence of E 2 ; 
non-classical membrane-initiated, in which an activated mem-
brane-associated ER initiates second-messenger pathways that 
phosphorylate different proteins including transcription factors; 
non-classical protein-protein interaction, in which the liganded 
ER interacts with other transcription factors bound to their re-
sponse elements in the DNA. Some examples of estrogen actions 
in the pituitary are shown under the corresponding mechanism. 
E 2 = 17  -Estradiol; ER = estrogen receptor; ERE = estrogen re-
sponse element; GF = growth factor; TF = transcription factor;
? = unknown transcription factor response element; PRL = pro-
lactin; GH = growth hormone. For details, see text. 
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ways with a direct effect on PRL gene expression in GH3 
cells. BMP-4/E 2 cross-talk on PRL transcriptional activ-
ity is mediated by the binding of a complex between 
Smad-1 and ER to a Smad-binding sequence on the PRL 
promoter. This novel signaling mechanism was shown to 
be specific for PRL regulation rather than a general effect, 
since no BMP-4/E 2 cross-talk was observed on GH secre-
tion  [41] . Recent studies in GH3 cells have shown that a 
functional ER  is essential for the maintenance of basal 
intracellular PRL levels, and that occupation rather than 
degradation of ER  by an antagonist is sufficient to in-
hibit PRL gene expression  [42, 43] .
 On the other hand, the control of PRL gene expression 
by ER  has not been extensively studied. Since the mouse 
pituitary does not express ER  , PRL production is unal-
tered in ER  -deficient (ER  KO) mice whereas it is im-
paired in ER  KO mice  [44] . However, since rat and hu-
man pituitaries express both ERs, estrogen regulation of 
PRL expression is likely to be different in mice versus rats 
and humans and should be re-examined. In fact, overex-
pression of ER  results in E 2 -induced PRL promoter ac-
tivity in GH3 cells, suggesting a potential role of this re-
ceptor in the control of PRL gene expression  [2] .
 In the absence of an available human pituitary cell 
line, most studies regarding the transcriptional regula-
tion of the human PRL (hPRL) gene have been performed 
by transfecting the hPRL promoter into GH3 cells. Tak-
ing into account that the rat pituitary cellular milieu may 
differ from the human’s and that cell lines are function-
ally dissimilar to primary cultures of pituitary cells, the 
observed effects may not be a reflection of what happens 
in the human pituitary in physiological conditions. Hu-
mans are not as responsive to the effects of estrogens on 
PRL expression as rats  [2] . This discrepancy between es-
trogen effects on rPRL and hPRL gene expression has 
been attributed to differences in the nucleotide sequence 
between rat and human EREs, which would lead to im-
paired ERE function in the hPRL promoter  [45] . It was 
suggested that despite a relatively small effect per se of 
estrogens in humans, they are nonetheless key factors to 
hPRL expression acting in concert with other endocrine 
or paracrine signals in the pituitary  [46] .
 An additional regulatory level of estrogen effects on 
PRL secretion beyond gene expression is PRL release, 
with seeming involvement of non-classical, membrane-
initiated estrogen actions. Physiological concentrations 
of E 2 or E 2 bound to BSA (E 2 -BSA), a conjugate unable to 
permeate the plasma membrane, were found to induce a 
rapid release of PRL from a subset of lactotropes through 
a cAMP-PKA independent pathway. This rapid PRL-se-
cretagogue effect of estrogens is achieved independently 
of DNA transcription or RNA translation and does not 
seem to involve classical nuclear receptors  [28] . Another 
study suggested that the activation of PKC signaling 
pathway through mER  is involved in PRL release from 
lactotropes in culture  [30] . Rapid induction of PRL re-
lease from GH3 cells has also been reported  [45] . Rapid, 
concentration-dependent increase in intracellular calci-
um levels and PRL release induced by E 2 and some xeno-
estrogens in GH3/B6 cell sublines heavily depend on the 
presence of mER   [48, 49] and may involve E 2 -induced 
ERK phosphorylation  [50, 51] .
 Growth Hormone Secretion 
 Although the involvement of estrogens in the synthe-
sis and release of GH from the anterior pituitary is well 
accepted, it is still unclear whether they regulate these ac-
tions by acting directly on somatotropes or through mod-
ulation of hypothalamic factors controlling GH secretion 
 [52] . Changes in circulating levels of sex steroids modu-
late GH secretion in many species, which accounts for 
sexual dimorphism in its secretory pattern  [52, 53] . In the 
rat, there are changes in the expression of GH mRNA 
during the estrous cycle that can be positively correlated 
with changes in circulating E 2  [54] . In cultured anterior 
pituitary cells from female rats, physiological concentra-
tions of E 2 increase spontaneous and GH-releasing hor-
mone (GHRH)-induced GH release as well as cellular GH 
content  [55] . More recently, physiological concentrations 
of E 2 were shown to increase the percentage of GH anti-
gen-bearing cells and of cells that express GH mRNA or 
GHRH receptors in vitro  [53] . Also, xenoestrogens were 
reported to induce GH mRNA and protein expression via 
an ER-mediated pathway both in vivo and in cultured 
GH3 cells  [56, 57] . In the MtT/S somatotrope cell line, 
which expresses ER  but not ER  , estrogens stimulate 
the transcription of the GH gene by acting at its proximal 
promoter  [58] . Since two Pit-1-binding sites but no ERE 
are found in this region, it has been suggested that ER 
might be acting through protein-protein interaction be-
tween Pit-1 and ER, similarly to one of the mechanisms 
described in the rPRL gene promoter  [38, 58] .
 Cell Proliferation and Death 
 It is generally accepted that estrogens act as powerful 
mitogens, exerting a sustained, dose-dependent trophic 
stimulus on anterior pituitary mitotic activity, which is 
ultimately responsible for the slightly larger pituitary in 
females compared to males and in parous compared to 




nomas in some rodent models. However, strong evidence 
supports the view that prolonged estrogen treatment in 
humans does not necessarily result in either hyperprolac-
tinemia, pituitary hyperplasia or progression to prolacti-
noma  [2, 59] . In fact, a recent report using female Wistar 
rats has shown that the mitotic effect of estrogens in the 
anterior pituitary is transient and does not lead to persis-
tent pituitary growth  [60] .
 It is well established that estrogens are able to induce 
pituitary tumors, most of which are PRL- or GH-secret-
ing tumors, only in certain rat strains or mice models 
[reviewed in  61 ]. Fisher 344 rats are highly responsive to 
estrogens, developing prolactinomas within weeks of es-
trogen treatment  [61] . Mechanisms that mediate estrogen 
action on lactotrope cell growth and prolactinoma for-
mation in this rat strain involve down-regulation of D2 
receptors, up-regulation of TGF  isoforms and other 
growth factors released by folliculo-stellate cells which 
act on lactotropes in a paracrine manner  [61] . Also, the 
suppression of inhibitory G (Gi) proteins and the increase 
in stimulatory G (Gs) proteins has been suggested as a 
mechanism for estrogen action on lactotrope cell growth 
and hormone production in Fisher 344 rats  [62] . In lacto-
trope cell lines, proliferation is more sensitive to estrogen 
treatment than PRL synthesis, since E 2 induces prolifera-
tion at much lower concentrations than those required to 
stimulate PRL gene expression  [63] . Although most estro-
gen actions on anterior pituitary cell proliferation appear 
to be mediated by ER   [42, 64] , TERP has also been sug-
gested as a candidate responsible for the regulation of PR1 
cell hypersensitive growth  [63] . It was recently reported 
that ER  proteosome-mediated degradation must follow 
antagonist occupation of the receptor to suppress GH3 
cell proliferation  [43] . A recent report has shown that 
EGF via activation of ErbB1 interacts with ligand-occu-
pied ER  to induce GH3 cell proliferation  [64] . Also, the 
cross-talk between BMP4 and estrogens results in stimu-
lation of GH3 cell proliferation probably through induc-
tion of the cell cycle regulator c-Myc  [65] . Recently, E 2 as 
well as weaker estrogens such as estrone and estriol, and 
some phytoestrogens were reported to elicit a prolifera-
tive response in the mER  -enriched pituitary tumor cell 
line GH3/B6/F10, an effect likely involving this mem-
brane receptor as well as MAPK signaling pathways and 
downstream transcription factor activation  [66, 67] .
 Most in vitro studies investigating effects of estrogens 
on pituitary cell growth have used estrogen-responsive 
cell lines. However, estrogen regulation of proliferation in 
tumor cell lines may not be representative of the normal 
physiology of anterior pituitary cell proliferation. Estro-
gen-induced lactotrope proliferation in primary culture 
seems to be a process regulated by complex interactions 
between different intracellular signal transduction path-
ways involving ER, PKA, and MAPK  [68] . Strong evi-
dence supports that E 2 exerts mitogenic and antimito-
genic actions in a cell-context and time-dependent man-
ner. The well-established mitogenic action of E 2 occurs 
only with long incubation periods and requires the syn-
thesis of local mediators whereas E 2 antimitogenic action 
has a short latency and needs the presence of growth fac-
tors  [68] . It has been suggested that E 2 acts selectively in 
signaling pathways of growth factors to counteract their 
mitogenic action  [69] . Also, the early mitogenic activity 
promoted by insulin on lactotropes is blocked by E 2 or 
E 2 -BSA, an action involving PKC, ERK1/2, Pit-1 and 
probably mER   [30] . Another study using lactotrope-en-
riched cells demonstrated that estrogens influence lacto-
trope proliferation independently of paracrine signals 
from other pituitary cell types probably through an auto-
crine mechanism involving growth factors produced by 
lactotropes themselves  [70] . Although it was originally 
suggested that the cross-talk between growth factor and 
ER signaling pathways was mediated by ligand-indepen-
dent growth factor activation of ER  [68] , a recent report 
has demonstrated the absence of such a mechanism in 
normal pituitary cells in culture, suggesting that ligand-
independent ER activation is a specific event likely re-
stricted to pituitary transformed cells such as GH3 and 
GH4C1 cells  [71] .
 Estrogens have also been shown to modulate apoptosis 
of anterior pituitary cells, particularly lactotropes and so-
matotropes, through different mechanisms involving 
both extrinsic and intrinsic apoptotic pathways [reviewed 
in  72 ]. The apoptotic action of the TNF-  /TNFR1 and 
Fas/FasL systems as well as dopamine in the anterior pi-
tuitary are estrogen-dependent  [73–75] . One mechanism 
involved in the estrogenic sensitization of anterior pitu-
itary cells to apoptosis includes an increase in the expres-
sion of Fas/FasL and TNF-  /TNFR1  [74, 76] . Also, E 2 per 
se induces apoptosis of anterior pituitary cells via chang-
es in the balance of pro- and antiapoptotic proteins of the 
Bcl-2 family and through activation of membrane-asso-
ciated ER   [31, 77] .
 Concluding Remarks 
 Although estrogens have traditionally been thought
to exert their multiple actions exclusively through acti-
vation of receptors acting as nuclear, ligand-dependent 
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transcription factors, it is now well accepted that the mo-
lecular mechanisms of estrogen action in the pituitary are 
more complex and involve interactions between multiple 
players. The activation of cytoplasmic/nuclear and mem-
brane ERs by estrogens or even other ligands initiates di-
verse intracellular signaling pathways which are not mu-
tually exclusive but interact with each other to contribute 
to the overall effect of estrogens on hormone secretion, 
cell proliferation and death in the pituitary. However, 
most studies are performed in cell lines and may not re-
flect the physiology of the normal pituitary, which  raises 
concerns about drawing conclusions regarding normal 
cell behavior based on data from cell lines. 
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